Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-47f74762e12054bd07cc18f7f2dc9dfb"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-47f74762e12054bd07cc18f7f2dc9dfb"/>
<resource>
<Composition>
<id value="composition-en-47f74762e12054bd07cc18f7f2dc9dfb"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-47f74762e12054bd07cc18f7f2dc9dfb"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-47f74762e12054bd07cc18f7f2dc9dfb</b></p><a name="composition-en-47f74762e12054bd07cc18f7f2dc9dfb"> </a><a name="hccomposition-en-47f74762e12054bd07cc18f7f2dc9dfb"> </a><a name="composition-en-47f74762e12054bd07cc18f7f2dc9dfb-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/12/806/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - ryzodeg</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/12/806/001"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mp47f74762e12054bd07cc18f7f2dc9dfb"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - ryzodeg"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet:</p><ol type="1"><li>What Ryzodeg is and what it is used for</li><li>What you need to know before you use Ryzodeg</li><li>How to use Ryzodeg</li><li>Possible side effects</li><li>How to store Ryzodeg</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What ryzodeg is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What ryzodeg is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Ryzodeg is used to treat diabetes mellitus in adults, adolescents and children from the age of 2 years. It helps your body reduce your blood sugar level.</p><p>This medicine contains two types of insulin:</p><ul><li>Basal insulin called insulin degludec, this has a long blood sugar-lowering effect.</li><li>Rapid-acting insulin called insulin aspart, this lowers your blood sugar soon after you inject it.</li></ul></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take ryzodeg"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="2. What you need to know before you take ryzodeg"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not use Ryzodeg</p><ul><li>if you are allergic to insulin degludec, insulin aspart or any of the other ingredients of this medicine (listed in section 6).</li></ul><p>Warnings and precautions Talk to your doctor, pharmacist or nurse before using Ryzodeg. Be especially aware of the following:</p><ul><li>Low blood sugar (hypoglycaemia) if your blood sugar is too low, follow the guidance for low blood sugar in section 4. * High blood sugar (hyperglycaemia) if your blood sugar is too high, follow the guidance for high blood sugar in section 4. * Switching from other insulin medicines the insulin dose may need to be changed if you switch from another type, brand or manufacturer of insulin. Talk to your doctor.</li><li>Pioglitazone used together with insulin, see Pioglitazone below.</li><li>Eye disorder fast improvements in blood sugar control may lead to a temporary worsening of diabetic eye disorder. If you experience eye problems, talk to your doctor.</li><li>Ensuring you use the right type of insulin always check the insulin label before each injection to avoid accidentally confusing Ryzodeg with other insulin products.</li></ul><p>If you have poor eyesight, please see section 3. Skin changes at the injection site The injection site should be rotated to help prevent changes to the fatty tissue under the skin, such as skin thickening, skin shrinking or lumps under the skin. The insulin may not work very well if you inject into a lumpy, shrunken or thickened area (see section 3 How to use Ryzodeg ). Tell your doctor if you notice any skin changes at the injection site. Tell your doctor if you are currently injecting into these affected areas before you start injecting in a different area. Your doctor may tell you to check your blood sugar more closely, and to adjust your insulin or your other antidiabetic medications dose.</p><p>Children and adolescents Ryzodeg can be used in adolescents and children from the age of 2 years with diabetes mellitus. Ryzodeg should be used with special caution in children 2 to 5 years old. The risk for very low blood sugar may be higher in this age group. There is no experience with the use of this medicine in children below the age of 2 years.</p><p>Other medicines and Ryzodeg Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines. Some medicines affect your blood sugar level, this may mean your insulin dose has to be changed.</p><p>Listed below are the most common medicines which may affect your insulin treatment.</p><p>Your blood sugar level may fall (hypoglycaemia) if you take:</p><ul><li>other medicines for diabetes (oral and injectable)</li><li>sulfonamides, for infections</li><li>anabolic steroids, such as testosterone</li><li>beta-blockers, for high blood pressure. They may make it harder to recognise the warning signs of too low blood sugar (see section 4 Warning signs of too low blood sugar )</li><li>acetylsalicylic acid (and other salicylates), for pain and mild fever</li><li>monoamine oxidase (MAO) inhibitors, for depression</li><li>angiotensin converting enzyme (ACE) inhibitors, for some heart problems or high blood pressure.</li></ul><p>Your blood sugar level may rise (hyperglycaemia) if you take:</p><ul><li>danazol, for endometriosis</li><li>oral contraceptives (birth control pills)</li><li>thyroid hormones, for thyroid problems</li><li>growth hormone, for growth hormone deficiency</li><li>glucocorticoids such as cortisone , for inflammation</li><li>sympathomimetics such as epinephrine (adrenaline), salbutamol or terbutaline, for asthma</li><li>thiazides, for high blood pressure or if your body keeps too much water (water retention).</li></ul><p>Octreotide and lanreotide: used to treat a rare condition involving too much growth hormone (acromegaly). They may increase or decrease your blood sugar level.</p><p>Pioglitazone: oral antidiabetic medicine used to treat type 2 diabetes mellitus. Some patients with long-standing type 2 diabetes mellitus and heart disease or previous stroke who were treated with pioglitazone and insulin experienced the development of heart failure. Inform your doctor immediately if you experience signs of heart failure such as unusual shortness of breath, rapid increase in weight or localised swelling (oedema).</p><p>If any of the above applies to you (or you are not sure), talk to your doctor, pharmacist or nurse.</p><p>Ryzodeg with alcohol If you drink alcohol, your need for insulin may change. Your blood sugar level may either rise or fall. You should therefore monitor your blood sugar level more often than usual.</p><p>Pregnancy and breast-feeding It is not known if Ryzodeg affects the baby in pregnancy or during breast-feeding. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Your insulin dose may need to be changed during pregnancy and after delivery. Careful control of your diabetes is needed in pregnancy. Avoiding too low blood sugar (hypoglycaemia) is particularly important for the health of your baby.</p><p>Driving and using machines Having too low or too high blood sugar can affect your ability to drive or use any tools or machines. If your blood sugar is too low or too high, your ability to concentrate or react might be affected. This could be dangerous to yourself or others. Ask your doctor whether you can drive if:</p><ul><li>you often get too low blood sugar</li><li>you find it hard to recognise too low blood sugar.</li></ul><p>Important information about some of the ingredients in Ryzodeg This medicine contains less than 1 mmol sodium (23 mg) per dose. This means that the medicine is essentially sodium-free .</p></div>
</text>
</section>
<section>
<title value="3. How to take ryzodeg"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take ryzodeg"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Always use this medicine exactly as your doctor has told you. Check with your doctor, pharmacist or nurse if you are not sure.</p><p>If you are blind or have poor eyesight and cannot read the dose counter on the pen, do not use the pen without help. Get help from a person with good eyesight who is trained to use the FlexTouch pre-filled pen.</p><p>The pre-filled pen can provide a dose of 1 80 units in one injection in steps of 1 unit.</p><p>Your doctor will decide with you:</p><ul><li>how much Ryzodeg you will need each day and at which meal(s)</li><li>when to check your blood sugar level and if you need a higher or lower dose.</li></ul><p>Flexibility in dosing time</p><ul><li>Always follow your doctor s recommendation for dose.</li><li>Ryzodeg can either be used once or twice each day.</li><li>Use with the main meal(s); you can change the time of dosing as long as Ryzodeg is dosed with the largest meal(s).</li><li>If you want to change your usual diet, check with your doctor, pharmacist or nurse first as a change in diet may alter your need for insulin.</li></ul><p>Based on your blood sugar level, your doctor may change your dose.</p><p>When using other medicines, ask your doctor if your treatment needs to be adjusted.</p><p>Use in elderly ( 65 years old) Ryzodeg can be used in elderly, but you may need to check your blood sugar level more often. Talk to your doctor about changes in your dose.</p><p>If you have kidney or liver problems If you have kidney or liver problems, you may need to check your blood sugar level more often. Talk to your doctor about changes in your dose.</p><p>Injecting your medicine Before you use Ryzodeg for the first time, your doctor or nurse will show you how to use the pre-filled pen.</p><ul><li>Check the name and strength on the label of the pen to make sure it is Ryzodeg 100 units/mL.</li></ul><p>Do not use Ryzodeg</p><ul><li>in insulin infusion pumps.</li><li>if the pen is damaged or has not been stored correctly (see section 5 How to store Ryzodeg ).</li><li>if the insulin does not appear clear and colourless.</li></ul><p>How to inject</p><ul><li>Ryzodeg is given as an injection under the skin (subcutaneous injection). Do not inject it into a vein or muscle.</li><li>The best places to inject are the front of your waist (abdomen), upper arms or the front of your thighs.</li><li>Change the place within the area where you inject each day to reduce the risk of developing lumps and skin pitting (see section 4).</li><li>Always use a new needle for each injection. Re-use of needles may increase the risk of blocked needles leading to inaccurate dosing. Dispose of the needle safely after each use.</li><li>Do not use a syringe to remove the solution from the pen to avoid dosing errors and potential overdose.</li></ul><p>Detailed instructions for use are provided on the other side of this leaflet.</p><p>If you use more Ryzodeg than you should If you use too much insulin, your blood sugar may get too low (hypoglycaemia), see advice in section 4 Too low blood sugar .</p><p>If you forget to use Ryzodeg If you forget a dose, inject the missed dose with your next large meal on that day and thereafter resume your usual dosing schedule. Do not inject a double dose to make up for a forgotten dose.</p><p>If you stop using Ryzodeg Do not stop using your insulin without talking to your doctor. If you stop using your insulin, this could lead to a very high blood sugar level and ketoacidosis (a condition with too much acid in the blood), see advice in section 4 Too high blood sugar .</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Hypoglycaemia (too low blood sugar) may occur very commonly with insulin treatment (may affect more than 1 in 10 people). It can be very serious. If your blood sugar level falls too much, you may become unconscious. Serious hypoglycaemia may cause brain damage and may be life-threatening. If you have symptoms of low blood sugar, take actions to increase your blood sugar level immediately. See advice in Too low blood sugar below.</p><p>If you have a serious allergic reaction (seen rarely) to the insulin or any of the ingredients in Ryzodeg, stop using this medicine and see a doctor straight away. The signs of a serious allergic reaction are:</p><ul><li>the local reactions spread to other parts of your body</li><li>you suddenly feel unwell with sweating</li><li>you start being sick (vomiting)</li><li>you experience difficulty in breathing</li><li>you experience rapid heartbeat or feeling dizzy.</li></ul><p>Other side effects include:</p><p>Common (may affect up to 1 in 10 people) Local reactions: Local reactions at the place you inject yourself may occur. The signs may include: pain, redness, hives, swelling and itching. The reactions usually disappear after a few days. See your doctor if they do not disappear after a few weeks. Stop using Ryzodeg and see a doctor straight away if the reactions become serious. For more information, see serious allergic reaction above.</p><p>Uncommon (may affect up to 1 in 100 people) Swelling around your joints: When you first start using your medicine, your body may keep more water than it should. This causes swelling around your ankles and other joints. This is usually only short-lasting.</p><p>Rare (may affect up to 1 in 1,000 people) This medicine can cause allergic reactions such as hives, swelling of the tongue and lips, diarrhoea, nausea, tiredness and itching.</p><p>Frequency not known (cannot be estimated from the available data) Skin changes at the injection site: If you inject insulin at the same place, the fatty tissue may either shrink (lipoatrophy) or thicken (lipohypertrophy). Lumps under the skin may also be caused by build- up of a protein called amyloid (cutaneous amyloidosis). The insulin may not work very well if you inject into a lumpy, shrunken or thickened area. Change the injection site with each injection to help prevent these skin changes.</p><p>General effects from diabetes treatment</p><ul><li>Too low blood sugar (hypoglycaemia)</li></ul><p>Too low blood sugar may happen if you: drink alcohol; use too much insulin; exercise more than usual; eat too little or miss a meal.</p><p>Warning signs of too low blood sugar these may come on suddenly:<br/>Headache; slurred speech; fast heartbeat; cold sweat, cool pale skin; feeling sick, feeling very hungry; tremor or feeling nervous or worried; feeling unusually tired, weak and sleepy; feeling confused, difficulty in concentrating; short-lasting changes in your sight.</p><p>What to do if you get too low blood sugar</p><ul><li>Eat glucose tablets or another high sugar snack, like sweets, biscuits or fruit juice (always carry glucose tablets or a high sugar snack, just in case).</li><li>Measure your blood sugar if possible and rest. You may need to measure your blood sugar more than once, as with all basal insulin products improvement from the period of low blood sugar may be delayed.</li><li>Wait until the signs of too low blood sugar have gone or when your blood sugar level has settled. Then carry on with your insulin as usual.</li></ul><p>What others need to do if you pass out<br/>Tell everyone you spend time with that you have diabetes. Tell them what could happen if your blood sugar gets too low, including the risk of passing out.</p><p>Let them know that if you pass out, they must:</p><ul><li>turn you on your side</li><li>get medical help straight away</li><li>not give you any food or drink because you may choke.</li></ul><p>You may recover more quickly from passing out with an injection of glucagon. This can only be given by someone who knows how to use it.</p><ul><li>If you are given glucagon, you will need sugar or a sugary snack as soon as you come round.</li><li>If you do not respond to a glucagon injection, you will have to be treated in a hospital.</li><li>If severe low blood sugar is not treated over time, it can cause brain damage. This can be short or long-lasting. It may even cause death.</li></ul><p>Talk to your doctor if:</p><ul><li><p>your blood sugar got so low that you passed out</p></li><li><p>you have used an injection of glucagon</p></li><li><p>you have had too low blood sugar a few times recently. This is because the dosing or timing of your insulin injections, food or exercise may need to be changed.</p></li><li><p>Too high blood sugar (hyperglycaemia)</p></li></ul><p>Too high blood sugar may happen if you: eat more or exercise less than usual; drink alcohol; get an infection or a fever; have not used enough insulin; keep using less insulin than you need; forget to use your insulin or stop using insulin without talking to your doctor.</p><p>Warning signs of too high blood sugar these normally appear gradually:<br/>Flushed, dry skin; feeling sleepy or tired; dry mouth, fruity (acetone) breath; urinating more often, feeling thirsty; losing your appetite, feeling or being sick (nausea or vomiting).<br/>These may be signs of a very serious condition called ketoacidosis. This is a build-up of acid in the blood because the body is breaking down fat instead of sugar. If not treated, this could lead to diabetic coma and eventually death.</p><p>What to do if you get too high blood sugar</p><ul><li>Test your blood sugar level.</li><li>Test your urine for ketones.</li><li>Get medical help straight away.</li></ul><p>Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store ryzodeg"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store ryzodeg"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the pen label and carton, after EXP . The expiry date refers to the last day of that month.</p><p>Before first use Store in a refrigerator (2 C to 8 C). Do not freeze. Keep away from the freezing element. Keep the cap on the pen in order to protect from light.</p><p>After first opening or if carried as a spare You can carry your Ryzodeg pre-filled pen (FlexTouch) with you and keep it at room temperature (not above 30 C) or in a refrigerator (2 C to 8 C) for up to 4 weeks.</p><p>Always keep the cap on the pen when you are not using it in order to protect from light.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Ryzodeg contains</p><ul><li>The active substances are insulin degludec and insulin aspart. Each mL of solution contains 100 units insulin degludec/insulin aspart in the ratio 70/30 (equivalent to 2.56 mg insulin degludec and 1.05 mg insulin aspart). Each pre-filled pen contains 300 units of insulin degludec/insulin aspart in 3 mL solution.</li><li>The other ingredients are glycerol, metacresol, phenol, sodium chloride, zinc acetate, hydrochloric acid and sodium hydroxide (for pH adjustment) and water for injections (see section 2).</li></ul><p>What Ryzodeg looks like and contents of the pack Ryzodeg is presented as a clear and colourless solution for injection in pre-filled pen (300 units per 3 mL).</p><p>Pack sizes of 1 (with or without needles), 5 (without needles) and multipack of 10 (2 x 5) (without needles) pre-filled pens of 3 mL. Not all pack sizes may be marketed.</p><p>Marketing Authorisation Holder<br/>Novo Nordisk A/S Novo All<br/>DK-2880 Bagsv rd, Denmark</p><p>Manufacturer</p><p>The manufacturer can be identified by the batch number printed on the slip of the carton and on the label:</p><p>If the second and third characters are P5, ZF or FG, the manufacturer is Novo Nordisk A/S, Novo All , DK-2880 Bagsv rd, Denmark.</p><p>If the second and third characters are T6, the manufacturer is Novo Nordisk Production SAS, Avenue d Orl ans, 28000 Chartres, France.</p><p>This leaflet was last revised in</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mp47f74762e12054bd07cc18f7f2dc9dfb"/>
<resource>
<MedicinalProductDefinition>
<id value="mp47f74762e12054bd07cc18f7f2dc9dfb"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mp47f74762e12054bd07cc18f7f2dc9dfb"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mp47f74762e12054bd07cc18f7f2dc9dfb</b></p><a name="mp47f74762e12054bd07cc18f7f2dc9dfb"> </a><a name="hcmp47f74762e12054bd07cc18f7f2dc9dfb"> </a><a name="mp47f74762e12054bd07cc18f7f2dc9dfb-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/12/806/001</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Ryzodeg 100 units/mL solution for injection in pre-filled pen</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/12/806/001"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName
value="Ryzodeg 100 units/mL solution for injection in pre-filled pen"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
